The UK's National Health Service (NHS) has rolled out a new value-based procurement (VBP) model for medical equipment and consumables, moving away from lowest upfront cost decisions to focus on lifetime value, patient outcomes, and system-wide savings. For medical aesthetics suppliers, this signals a growing emphasis on clinical efficacy, patient experience, and total cost of ownership in public healthcare purchasing, which may influence private clinic procurement trends.
What the new model means
The NHS in England is now implementing a procurement approach that evaluates factors such as patient outcomes, workforce impact, and wider system costs, rather than just the purchase price. A trial involving continence products reported reduced product usage and leakages, improved staff satisfaction, and lower overall care costs. This shift reflects broader healthcare trends toward value-based care, which could extend to aesthetic medical devices and consumables as clinics and hospitals seek products that demonstrate long-term cost-effectiveness and patient benefit.
Industry reaction and data
Hygiene and health company Essity, maker of TENA incontinence products, welcomed the rollout. Richard Maddison from Essity said: "For too long, procurement decisions have often been driven by the lowest purchase price rather than the outcomes delivered for patients and the wider healthcare system. Value-based procurement recognises that the cheapest product is not always the most cost-effective option." Essity's 2025 Freedom of Information data found 53% of 110 NHS Trusts had capped continence product supply, with 34% limiting patients to three products daily and 66% to four. The NHS spends an estimated £5.13 billion annually on incontinence-related care, and Essity projects potential savings of £500 million per year from VBP adoption.
Regulatory and channel signals
The NHS faces rising demand and financial pressures, driving this procurement overhaul. Supporters argue VBP can reduce complications like urinary tract infections and skin damage, lower avoidable hospital admissions, and improve patient mobility and wellbeing. For medical aesthetics distributors and clinic buyers, this model may influence UK private sector purchasing as well, with increased demand for devices and consumables that offer proven clinical outcomes, reduced waste, and better patient experience. Suppliers should prepare to provide data on product lifecycle costs, clinical evidence, and workforce impact.
Sourcing context
Essity's research among 500 healthcare professionals found 71% believe patients could be more independent with improved product quality and fit. Maddison added: "Procurement is not simply a purchasing exercise. The products selected by the NHS can have a profound impact on a person's dignity, confidence, independence, and overall wellbeing." For aesthetic device and consumable OEMs, this underscores the importance of demonstrating value beyond price, including patient satisfaction, ease of use, and long-term cost efficiency, to align with evolving procurement standards in the UK and potentially other markets.
Source: Read the original report | Published: June 17, 2026